Not provided
Not provided
Not provided
Not provided
Not provided
feasibility problem
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study evaluates the dose received by the prostate with in vivo dosimetry when delivering image guided radiation therapy (IGRT) associated with intensity modulated radiation therapy (IMRT) for patients with localized prostate cancer using two repositioning techniques: fiduciary markers or soft tissues.
10 participants will receive a cone beam computed tomography (CBCT) repositioning, while the other 10 will receive a kV imaging of fiducial marker repositioning. The principal objective is to evaluate and compare the dose received by the prostate using two repositioning techniques.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| CBCT | Other | cone beam computed tomography (CBCT) repositioning |
|
| fiducial markers | Other | kV imaging of fiducial marker repositioning |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CBCT | Other | 10 participants will receive a cone beam computed tomography (CBCT) repositioning |
| |
| Measure | Description | Time Frame |
|---|---|---|
| dosimetry (measurement of the absorbed dose, delivered to prostate, by ionizing radiation) | 8 weeks |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Gilles CREHANGE, MD, PhD | Centre Georges François Leclerc | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centre Georges-François Leclerc | Dijon | 21000 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| fiducial marker (kV imaging) |
| Other |
10 participants will receive a kV imaging of fiducial marker repositioning. |
|
| IGRT Associated With IMRT | Radiation |
|
| ID | Term |
|---|---|
| D011471 | Prostatic Neoplasms |
| ID | Term |
|---|---|
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D005832 | Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D011469 | Prostatic Diseases |
| D052801 | Male Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D057918 | Fiducial Markers |
| D050397 | Radiotherapy, Intensity-Modulated |
| ID | Term |
|---|---|
| D012015 | Reference Standards |
| D014894 | Weights and Measures |
| D008919 | Investigative Techniques |
| D019736 | Prostheses and Implants |
| D004864 | Equipment and Supplies |
| D055618 | Radiation Equipment and Supplies |
| D020266 | Radiotherapy, Conformal |
| D011881 | Radiotherapy, Computer-Assisted |
| D011878 | Radiotherapy |
| D013812 | Therapeutics |
Not provided
Not provided